Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05291871 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity of Fractional Dose of the HPV Vaccines
A Phase 4 study of HPV Infection and HPV Vaccine, sponsored by University of Washington.
- Active
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT05291871: Active Phase 4 study of HPV Infection and HPV Vaccine, sponsored by University of Washington.
NCT05291871 is a Phase 4 study of HPV Infection and HPV Vaccine that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 92 participants, below the 229-participant average among 13 other HPV Infection trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05291871, a Phase 4 study of HPV Infection and HPV Vaccine, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months
Primary Outcome
To describe the changes in vaccine-type HPV antibody detection measured by Luminex assay between baseline and 12 months after vaccination.
Conditions Studied
Interventions
- BIOLOGICAL HPV vaccine
Study Locations (1)
Washington
- University of Washington Virology Research Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What the registry record for NCT05291871 still lists
NCT05291871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 229-participant average among 13 other HPV Infection trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with HPV Infection appearing as the primary indexed condition, and to 1 intervention - of which HPV vaccine is the first listed.
NCT05291871 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05291871 about?
NCT05291871 is a clinical study titled "Immunogenicity of Fractional Dose of the HPV Vaccines". This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and ...
What is the current status of trial NCT05291871?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2022-06-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05291871 study?
This clinical trial studies the following conditions: HPV Infection, HPV Vaccine.
What interventions are being tested in trial NCT05291871?
The interventions under investigation include: HPV vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05291871?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05291871 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05291871's enrollment target sits among peer trials
92 9th of 13 higher than 5 of 13 other HPV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HPV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
ACTIVE NOT RECRUITING · Phase 4
-
Intradermal, Fractional Dose of HPV Vaccines:
ACTIVE NOT RECRUITING · Phase 4
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI